

ENGOT Ov-17 Trial MITO 16b; MANGO-OV2b Study Design


ARM 1: 6 cycles

CBDCA AUC5 + PAC 175 mg/m² q3w
or
CBDCA AUC4, d1 + GEM 1000mg /m², d1&8 q3w
or
CBDCA AUC5+PLD 30mg/m² q4w


ARM 2*: 6 cycles

CBDCA AUC5 + PAC 175 mg/m² q3w
Plus bevacizumab** 15mg/kg q3w
or
CBDCA AUC4, d1 + GEM 1000mg /m², d1&8 q3w
Plus bevacizumab 15mg/kg q3w
or
CBDCA AUC5+PLD 30mg/m² q4w
Plus bevacizumab 10mg/kg q2w

- Ovarian Ca
- Platinum-sensitive
- Previous Bevacizumab
- ECOG 0-2
- Availability of samples for translational res.
- No Beva contraindications



ENGOT Ov-17 Trial MITO 16b; MANGO-OV2b Enrollment 16/05/2016



Enrollment by Group

GROUP	N. Patients
MITO	154
GINECO	75
MANGO	50
SAKK	14
HeCOG	7
BGOG	-
Total	300